Despite the success of CAR-T therapies in patients with leukemia and lymphoma there has been little progress in deploying this modality against solid tumors.
Cheaper, Faster, Better
The use of Rescue Proteins to treat patients' own immune cells has several key advantages over existing cell therapy treatments.
Duration and Durability
Restores cytokine receptor pathways for up to 5 days after a 1 hour incubation – eliminating the need for potentially toxic IL-2 treatment.
No Preconditioning
Preconditioning may be the cause for infections and morbidity in CAR T-cell treated patients and our process allows the patient to keep their immune system intact.
Very Low Cell Dose Required
As low as a million cells/kg has been used to see an effect, reducing the need for extensive apheresis.
Short Turnaround, Simplified Manufacturing
A one hour incubation eliminates need for lengthy cGMP production, significantly reducing the overall cost.
Differentiated
This protein based, non-genetic, highly specific approach with a well characterized mechanism of action also has built in safety features because an existing approved drug can shut down our newest Rescue Protein.